Antibiotic resistance is a serious and steadily growing medical threat. One possible mechanism of resistance is the expression of β-lactamases, which have the ability to hydrolyze β-lactam antibiotics. The most worrisome group of these enzymes are metallo-β-lactamases (MBLs) which employ catalytic Zn ions to perform the hydrolysis reaction. Mechanistically they are different from other β-lactamases (such as serine hydrolases) and they are resistant to the clinically available β-lactamase inhibitors. MBLs have been extensively studied. Structurally they exhibit a considerable diversity of their binding sites and substrate specificities, making inhibitor design difficult. Unfortunately, a high level of noise in the structural information, in particular in the aspect of enzyme-ligand binding, makes it difficult to carry out detailed comparisons among structures, not to mention drawing of meaningful biological or medical conclusions from such comparisons.
